Invest5 publishers3 min readPublished
Qualcomm buys Huawei patents 25 years after Huawei paid its first licence fee to Qualcomm
Huawei puts its expected patent-licensing contract value above $6.9 billion after Qualcomm signed a 5G cross-licence and agreed to buy some of its US patents. Whether that income recurs depends on how the deal splits between net royalties and a one-time patent sale.
The Investor · Invest desk
Drafted by a language model from the sources cited here and checked against its claim ledger before publication. How we use AISend a correction

What happened
- Huawei says it is the first agreement under which it licenses and assigns compute, AI and networking patents to Qualcomm.
- Huawei's first IP licensing payment went to Qualcomm in 2001, and its first licensing revenue came from Motorola in 2011.
- The deal follows by weeks a Huawei cross-licensing agreement with HP covering patents used in Wi-Fi technology.
Compiled by The InvestorSomething wrong?How this is made
Why it matters
- contradiction Dow Jones describes a cross-licence plus a patent sale while Nikkei calls Qualcomm the net payer, and the split decides whether Huawei is booking recurring royalties or a one-time sale.
- exposure Part of the total Huawei quoted after signing now depends on a US review of a sanctioned Chinese company moving US patents to a US chip designer.
- precedent If the deal closes, a 5G licence with Qualcomm as net payer gives Huawei a reference contract when it prices the next 5G licensee.
Huawei's $6.9 billion is an expected contract value across the patent-licensing agreements it has signed so far, and the company gave the figure after the Qualcomm signing [7]. It appears to include a deal that closes only once regulators approve it [6]. Nikkei reports that approval means a US review [11].
The two companies have signed several agreements since the first one, more than two decades ago [9]. Huawei made its first IP licensing payment to Qualcomm in 2001 and earned its first licensing revenue, from Motorola, in 2011 [8]. That is ten years as a payer only [1]. The deal announced on October 5 [12] comes fifteen years after that first receipt and 25 years after the first payment [2][3]. Nikkei reports it would make Qualcomm the net payer for the first time [10].
The two reports describe the cash differently. Dow Jones has a multiyear cross-licence across 5G, compute, AI and networking, plus a Qualcomm purchase of some Huawei US patents [1][2]. The net-payer language is Nikkei's [10]. For Huawei those are separate kinds of money. A net royalty on a multiyear cross-licence comes in for each year the contract runs. A patent sale is paid once, and afterwards Qualcomm owns those US patents outright [2].
What Qualcomm is not doing in compute, AI and networking is taking a licence alone. It is buying patents in fields where, Huawei says, it had never before licensed or assigned patents to Qualcomm [4]. Ownership ends any running fee Qualcomm would otherwise pay on those patents.
US reviewers can clear the deal as signed [11]. Huawei would then have a 5G licence with Qualcomm as net payer to cite in its next negotiation [3][10]. They can clear the cross-licence and object to moving US patents to Qualcomm [2], leaving a balance only the two companies can size. Or they can stop it, and part of the total Huawei published after signing [7] goes with it.
Dow Jones presents the Qualcomm deal, and the HP Wi-Fi cross-licence signed weeks earlier [5], as evidence that Huawei remains a top patent holder despite years of US sanctions that limited its access to advanced semiconductors [13]. I think that holds in its narrow form: sanctions restricted what Huawei can buy, and two technology companies still signed licensing deals with it within weeks of each other [1][5]. The companies did not disclose terms [6], and neither report describes a dispute between them. On that evidence, this deal alone does not reprice royalty income or litigation risk across the chip and telecoms sector.
The view is wrong if reported terms show the patent sale is most of the value and the 5G net balance is small. Huawei would then have sold US assets for a single payment, and a recurring-royalty reading of the $6.9 billion [7] would overstate what comes back each year.
What to watch
- The outcome of the US regulatory review the deal needs before it can close, and whether any conditions fall on the patent assignment to Qualcomm.
- Any reporting that splits the deal's value between the net cross-licence balance and the purchase of Huawei's US patents.
- Huawei's next update to its expected licensing contract value above $6.9 billion, and which licensees it adds after HP and Qualcomm.